{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:18:07Z","timestamp":1791883087082,"version":"4.3.4"},"reference-count":38,"publisher":"The Journal of Health Economics and Outcomes Research","issue":"1","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["jheor.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec id=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Traditional quality-adjusted life-year (QALY)\u2013based cost-effectiveness analyses (CEAs) may inadvertently penalize treatments extending survival in populations with disabilities. Duchenne muscular dystrophy (DMD) is a rare, progressive disease diagnosed during childhood with significant morbidity, premature mortality, and considerable healthcare costs. The impact of delaying mortality on CEAs for DMD is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"objective\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the impact of delaying nonfatal progression and\/or mortality using a QALY-based CEA for three hypothetical DMD treatments, assessing if treatment value increases by delaying morbidity and\/or mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A previously published, five-state QALY-based cost-effectiveness model for analyzing treatments in an early ambulatory DMD population was replicated, validated, and adapted to include an early nonambulatory (ENA) population. Maximum annual treatment price was determined for three hypothetical treatments individually compared for each population with standard of care (SoC): (A) delays nonfatal progression and mortality; (B) delays nonfatal progression; or (C) delays mortality. A 10-year delay was assessed for all three. Willingness-to-pay (WTP) thresholds ranged from $50\u2009000 to $200\u2009000\/QALY.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In both populations, QALYs gained vs SoC were highest for the hypothetical treatment delaying both nonfatal progression and mortality. Maximum annual treatment price was highest for the hypothetical treatment delaying nonfatal progression only (both populations and all WTP thresholds). Delaying mortality alone consistently had a negative annual valuation (not cost-effective even at $0 price), ranging from $\u22128685 to $\u22122148 (EA population) and $\u221213\u2009253 to $\u22123278 (ENA population). For all treatments, valuation for the ENA population was consistently lower.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"discussion\">\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These model results illustrate that delaying both nonfatal progression and mortality is less valuable in a traditional CEA than delaying nonfatal progression alone, even when the additional survival is at the patient\u2019s best possible health and lowest costs. These results emphasize the significant shortcomings of QALY-based CEAs for assessing the value of potential life-extending treatments for progressive, disabling diseases, like DMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results suggest that within a traditional CEA, delaying mortality decreases a DMD treatment\u2019s value estimate, countering society\u2019s values and norms for desired life extension in vulnerable populations. These limitations must be carefully considered when interpreting model results and highlight the need for applying other value assessment methodologies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36469\/001c.156118","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:02:51Z","timestamp":1771434171000},"update-policy":"https:\/\/doi.org\/10.36469\/00001","source":"Crossref","is-referenced-by-count":1,"title":["The Paradox of Life Extension with Traditional Cost-Effectiveness Analysis: A Case Study with Duchenne Muscular Dystrophy"],"prefix":"10.36469","volume":"13","author":[{"given":"Lauren","family":"Sedita","sequence":"first","affiliation":[{"name":"Sarepta Therapeutics, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Klimchak","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Perfetto","sequence":"additional","affiliation":[{"name":"University of Maryland, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Gooch","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Malone","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22273","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"K. Bushby","year":"2010","journal-title":"Lancet Neurol"},{"issue":"2","key":"ref2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1474-4422(09)70272-8","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care","volume":"9","author":"K. Bushby","year":"2010","journal-title":"Lancet Neurol"},{"issue":"6","key":"ref3","doi-asserted-by":"publisher","first-page":"S318","DOI":"10.1016\/j.jval.2024.03.1997","article-title":"PCR118 Education and employment among individuals with Duchenne muscular dystrophy: results from a caregiver survey","volume":"27","author":"B. Innis","year":"2024","journal-title":"Value Health"},{"issue":"6","key":"ref4","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1007\/s12325-022-02117-1","article-title":"Disease progression stages and burden in patients with Duchenne muscular dystrophy using administrative claims supplemented by electronic medical records","volume":"39","author":"J. Iff","year":"2022","journal-title":"Adv Ther"},{"issue":"3","key":"ref5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s11136-019-02355-x","article-title":"Characterizing health state utilities associated with Duchenne muscular dystrophy: a systematic review","volume":"29","author":"S. M. Szabo","year":"2020","journal-title":"Qual Life Res"},{"issue":"6","key":"ref6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/WNL.0000000000000669","article-title":"The burden of Duchenne muscular dystrophy: an international, cross-sectional study","volume":"83","author":"E. Landfeldt","year":"2014","journal-title":"Neurology"},{"key":"ref7","article-title":"Deflazacort, eteplirsen, and golodirsen for Duchenne muscular dystrophy: effectiveness and value","author":"Institute for Clinical and Economic Review"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.vhri.2023.08.004","article-title":"Early cost-utility analysis of ataluren and eteplirsen in the treatment of Duchenne muscular dystrophy in Egypt","volume":"38","author":"Z. Shehata","year":"2023","journal-title":"Value Health Reg Issues"},{"key":"ref9","article-title":"Ataluren for treating Duchenne muscular dystrophy with a nonsensemutation in the dystrophin gene","author":"National Institute for Health and Clinical Excellence","year":"2023"},{"key":"ref10","article-title":"2020-2023 Value Assessment Framework","author":"Institute for Clinical and Economic Review"},{"issue":"8","key":"ref11","doi-asserted-by":"publisher","first-page":"E639","DOI":"10.1001\/amajethics.2021.639","article-title":"How does cost-effectiveness analysis inform health care decisions?","volume":"23","author":"D. D. Kim","year":"2021","journal-title":"AMA J Ethics"},{"issue":"9","key":"ref12","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"P. J. Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"ref13","article-title":"2020-2023 Value Assessment Framework","author":"Institute for Clinical and Economic Review"},{"issue":"8","key":"ref14","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","article-title":"United States valuation of EQ-5D-5L health states using an international protocol","volume":"22","author":"A. S. Pickard","year":"2019","journal-title":"Value Health"},{"key":"ref15","article-title":"Assessing Technologies That Are Not Cost-Effective at a Zero Price","author":"S. Davis","year":"2014"},{"issue":"3","key":"ref16","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jval.2023.01.004","article-title":"The zero-price conundrum: exploration of scenarios where a clinically effective new drug might not be cost-effective at zero price","volume":"26","author":"D. Mladsi","year":"2023","journal-title":"Value Health"},{"issue":"3","key":"ref17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40258-023-00869-7","article-title":"Comparing preferences for disease profiles: a discrete choice experiment from a US societal perspective","volume":"22","author":"K. M. Johnston","year":"2024","journal-title":"Appl Health Econ Health Policy"},{"issue":"12","key":"ref18","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1016\/s0277-9536(02)00244-7","article-title":"The rule of rescue","volume":"56","author":"J. McKie","year":"2003","journal-title":"Soc Sci Med"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/(SICI)1099-1050(199902)8:1<25::AID-HEC398>3.0.CO;2-H","article-title":"Incorporating societal concerns for fairness in numerical valuations of health programmes","volume":"8","author":"E. Nord","year":"1999","journal-title":"Health Econ"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/(SICI)1099-1050(199703)6:2<117::AID-HEC256>3.0.CO;2-B","article-title":"Intergenerational equity: an exploration of the 'fair innings' argument","volume":"6","author":"A. Williams","year":"1997","journal-title":"Health Econ"},{"issue":"9","key":"ref21","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1007\/s11136-018-1891-7","article-title":"Engaging patients and caregivers in prioritizing symptoms impacting quality of life for Duchenne and Becker muscular dystrophy","volume":"27","author":"I. L. Hollin","year":"2018","journal-title":"Qual Life Res"},{"issue":"1","key":"ref22","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.1016\/j.jval.2021.04.903","article-title":"PNS48 Do US commercial health plans cite ICER reports in their specialty drug coverage policies? An empirical analysis","volume":"24","author":"D. Enright","year":"2021","journal-title":"Value Health"},{"issue":"5","key":"ref23","doi-asserted-by":"publisher","first-page":"e0213649","DOI":"10.1371\/journal.pone.0213649","article-title":"Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: a qualitative preference study of patients and parents","volume":"14","author":"H. Landrum Peay","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"ref24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13023-019-1069-6","article-title":"Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best-worst scaling experiment in caregivers and adult patients","volume":"14","author":"R. S. Paquin","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"ref25","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.clinthera.2014.04.011","article-title":"A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy","volume":"36","author":"H. L. Peay","year":"2014","journal-title":"Clin Ther"},{"issue":"2","key":"ref26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/13571516.2011.584428","article-title":"Real option value and path dependence in oncology innovation","volume":"18","author":"J. Cook","year":"2011","journal-title":"Int J Econ Bus"},{"issue":"2","key":"ref27","doi-asserted-by":"publisher","DOI":"10.1515\/1558-9544.1306","article-title":"The option value of innovation","volume":"15","author":"J. Thornton Snider","year":"2012","journal-title":"Forum Health Econ Policy"},{"issue":"5","key":"ref28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40273-024-01367-x","article-title":"Economic evaluations of treatments for Duchenne muscular dystrophy: the caregiver QALY trap","volume":"42","author":"E. Landfeldt","year":"2024","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"ref29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/mus.27429","article-title":"Labor market participation and productivity costs for female caregivers of minor male children with Duchenne and Becker muscular dystrophies","volume":"64","author":"R. H. Soelaeman","year":"2021","journal-title":"Muscle Nerve"},{"issue":"3","key":"ref30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s40273-023-01321-3","article-title":"Recommendations for emerging good practice and future research in relation to family and caregiver health spillovers in health economic evaluations: a report of the SHEER Task Force","volume":"42","author":"E. Henry","year":"2024","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"ref31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jval.2025.08.018","article-title":"Mental health, quality of life, and work functioning of parents of children who have died of spinal muscular atrophy","volume":"29","author":"T. A. Lavelle","year":"2026","journal-title":"Value Health"},{"issue":"1","key":"ref32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-022-02182-3","article-title":"Patients' access to rare neuromuscular disease therapies varies across US private insurers","volume":"17","author":"N. M. Margaretos","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.04.021","article-title":"Quality-adjusted life-years, quality-adjusted life-year-like measures, or neither? The debate continues","author":"N. J. Devlin","year":"2024","journal-title":"Value Health"},{"issue":"5","key":"ref34","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s40258-014-0112-y","article-title":"Ethical objections against including life-extension costs in cost-effectiveness analysis: a consistent approach","volume":"12","author":"A. Gandjour","year":"2014","journal-title":"Appl Health Econ Health Policy"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.04.018","article-title":"The value of the quality-adjusted life years","author":"R. J. Willke","year":"2024","journal-title":"Value Health"},{"key":"ref36","article-title":"Appraising life-extending, end of life treatments","author":"National Institute for Health and Clinical Excellence","year":"2009"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.07.008","article-title":"Discriminatory properties of quality-adjusted life year based cost-effectiveness analyses for patients with disabilities: a Duchenne muscular dystrophy case study","author":"A. C. Klimchak","year":"2024","journal-title":"Value Health"},{"issue":"1","key":"ref38","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1080\/13696998.2022.2090152","article-title":"QALYs and ambulatory status: societal preferences for healthcare decision making","volume":"25","author":"L. L. Freath","year":"2022","journal-title":"J Med Econ"}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jheor.org\/article\/156118-the-paradox-of-life-extension-with-traditional-cost-effectiveness-analysis-a-case-study-with-duchenne-muscular-dystrophy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:35:48Z","timestamp":1779885348000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/156118-the-paradox-of-life-extension-with-traditional-cost-effectiveness-analysis-a-case-study-with-duchenne-muscular-dystrophy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.36469\/001c.156118","relation":{},"ISSN":["2327-2236"],"issn-type":[{"value":"2327-2236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]}}}